bruin mcl-321: pirtobrutinib en lcm sin tratamiento previo con inhibidores btk
Published 2 years ago • 27 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:10
bruin mcl-321: pirtobrutinib vs investigator choice of btk inhibitor in btk inhibitor-naive mcl
-
1:44
bruin mcl-321: pirtobrutinib in btki naïve mcl
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
1:59
updated results from the bruin study: pirtobrutinib in the treatment of mcl
-
2:12
pirtobrutinib for btk inhibitor-naïve and btk inhibitor pre-treated r/r mcl
-
1:08
phase i/ii bruin study: pirtobrutinib in patients intolerant to a covalent btk inhibitor
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
1:18
pirtobrutinib: the next generation of btk inhibitors
-
3:07
bruin study: updated two-year subgroup analysis of pirtobrutinib for btki pre-treated mcl
-
1:08
pirtobrutinib in cll: updates from the bruin cll-321 trial
-
1:35
pirtobrutinib in r/r fl: results from the bruin study
-
1:18
bruin study cohort update: pirtobrutinib for patients with mcl
-
1:51
updates on the phase i/ii bruin study and the role of pirtobrutinib in mcl
-
1:42
zanubrutinib plus rituximab in first-line mcl therapy
-
3:01
updates from the bruin study – long-term safety of pirtobrutinib in r/r mcl
-
2:34
bruin study update: analysis of the mechanisms of resistance to pirtobrutinib in cll
-
2:23
efficacy of pirtobrutinib in patients with r/r mcl previously treated with a covalent btki
-
1:32
selecting btk inhibitors for patients with mcl
-
1:57
the pharmacokinetics of pirtobrutinib